SPHERE - Study of Perinatal, paediatric and adolescent Health : Epidemiological Research and Evaluation
Equipe constitutive du CERPOP, UMR1295, unité mixte de recherche Inserm – Université Toulouse III Paul Sabatier
Justine BÉNÉVENT •  chercheure



2023
  1. Balon M, Tessier S, Damase-Michel C, Cottin J, Lambert A, Thompson MA, Benevent J, Lacroix I. Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age? Therapie. 2023 Mar-Apr;78(2):165-173. doi: 10.1016/j.therap.2022.11.005.
  2. Benevent J, Araujo M, Beau AB, Sicard D, Sommet A, Hurault-Delarue C, Lacroix I, Damase-Michel C. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database. Infection. 2023 Feb;51(1):137-146. doi: 10.1007/s15010-022-01861-4.
  3. Benevent J, Araujo M, Karki S, Delarue-Hurault C, Waser J, Lacroix I, Tebeka S, Damase-Michel C. Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database. J Clin Psychiatry. 2023 Jul 10;84(4):22m14734. doi: 10.4088/JCP.22m14734.
  4. Saint-Lary L, Bénévent J, Damase-Michel C, Vayssière C, Leroy V, Sommet A. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023 Jan 30;23(1):80. doi: 10.1186/s12884-023-05347-5.
2022
  1. Bénévent J, Hurault-Delarue C, Araujo M, Revet A, Sommet A, Lacroix I, Damase-Michel C. Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study. Front Psychiatry. 2022 Mar 22;13:795890. doi: 10.3389/fpsyt.2022.795890.
  2. Gosset A, Denuelle M, Valton L, Sommet A, Bénévent J, Tremollières F. Interactions between antiseizure medications and contraception: A study about the knowledge of patients and their specialist physicians. Epilepsy Behav. 2022 Apr;129:108627. doi: 10.1016/j.yebeh.2022.108627.
2021
  1. Araujo M, Vabre C, Bénévent J, Sommet A, Damase-Michel C, Hurault-Delarue C, Lacroix I. Risk of Pregnancy Termination and Congenital Anomalies After Domperidone Exposure: A Study in the EFEMERIS Database. Drug Saf. 2021 Jul;44(7):787-796. doi: 10.1007/s40264-021-01077-9.
  2. Cottin J, Benevent J, Khettar S, Lacroix I. COVID-19 vaccines and pregnancy: What do we know? Therapie. 2021 Jul-Aug;76(4):373-374. doi: 10.1016/j.therap.2021.05.011.
  3. Hjorth S, Hemmingsen CH, Bénévent J, Broe A, Pottegaard A, Mørch LS, Leinonen MK, Kjaer SK, Hargreave M, Nordeng H. Maternal Medication Use and Childhood Cancer in Offspring-Systematic Review and Considerations for Researchers. Am J Epidemiol. 2021 Nov 2;190(11):2487-2499. doi: 10.1093/aje/kwab154.
  4. Hurault-Delarue C, Araujo M, Vabre C, Bénévent J, Damase-Michel C, Lacroix I. What changes in prescription patterns of antiemetic medications in pregnant women in France? Fundam Clin Pharmacol. 2021 Dec;35(6):1159-1167. doi: 10.1111/fcp.12681. 
2020
  1. Lacroix I, Bénévent J, Damase-Michel C. Chloroquine and hydroxychloroquine during pregnancy: What do we know? Therapie. 2020 Jul-Aug;75(4):384-385. doi: 10.1016/j.therap.2020.05.004.
2019
  1. Araujo M, Hurault-Delarue C, Bouilhac C, Petiot D, Bénévent J, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C, Lacroix I. Non-steroidal anti-inflammatory drug prescriptions from the 6th month of pregnancy: impact of advice from health authorities. Fundam Clin Pharmacol. 2019 Oct;33(5):581-588. doi: 10.1111/fcp.12460.
  2. Baudou E, Bénévent J, Montastruc JL, Touati G, Hachon LeCamus C. Adverse Effects of Treatment with Valproic Acid during the Neonatal Period. Neuropediatrics. 2019 Feb;50(1):31-40. doi: 10.1055/s-0038-1676035.
  3. Benevent J, Araujo M, Hurault-Delarue C, Montastruc JL, Sommet A, Lacroix I, Damase-Michel C. Pharmacoepidemiology in pregnancy. Therapie. 2019 Apr;74(2):289-300. doi: 10.1016/j.therap.2018.11.014.
  4. Bénévent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C. POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. Drug Saf. 2019 Jan;42(1):45-54. doi: 10.1007/s40264-018-0712-9.
  5. Bénévent J, Hurault-Delarue C, Araujo M, Montastruc F, Montastruc JL, Lacroix I, Damase-Michel C. Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. Fundam Clin Pharmacol. 2019 Jun;33(3):314-326. doi: 10.1111/fcp.12428.
  6. Montastruc JL, Bénévent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M, Sommet A. What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie. 2019 Apr;74(2):169-174. doi: 10.1016/j.therap.2018.08.001.
  7. Montastruc JL, Montastruc F, Bénévent J, Lacroix I, Durrieu G, Du Plantier JM, Bagheri H, Sommet A, Damase-Michel C. Tintin in the Land of Drugs: A pharmacological, pharmacovigilance approach. Therapie. 2019 Jun;74(3):445-447. doi: 10.1016/j.therap.2019.01.002.
  8. Sommet A, Bénévent J, Rousseau V, Chebane L, Douros A, Montastruc JL, Montastruc F. What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®. J Gen Intern Med. 2019 Apr;34(4):502-503. doi: 10.1007/s11606-018-4774-2.